Literature DB >> 29534610

Development of a rapid liquid chromatography tandem mass spectrometry method for the quantitation of serum dexamethasone and its clinical verification.

James M Hawley1, Laura J Owen1,2, Miguel Debono3, John Newell-Price3, Brian G Keevil1,2.   

Abstract

Background Measurement of serum dexamethasone during the overnight dexamethasone-suppression test has been recommended to reduce false-positive results when investigating Cushing's syndrome or increasingly commonly found adrenal incidentalomas. Despite this, there remains a paucity of well-validated dexamethasone methods currently available. Here, we describe the development of a rapid and sensitive liquid chromatography tandem mass spectrometry serum dexamethasone assay and verify its utility in a cohort of postmenopausal females. Method Isotopically labelled internal standard was added to samples prior to supported liquid extraction. Extracts were analysed using liquid chromatography tandem mass spectrometry in the positive electrospray ionization mode. Multiple reaction monitoring was used to detect dexamethasone and its corresponding internal standard transitions. Normal healthy postmenopausal women ( n = 95) were recruited and underwent an overnight dexamethasone suppression test, with serum dexamethasone and cortisol measurements at 09:00 after administration of oral dexamethasone 1 mg at 23:00 the night before. Results Mean intra- and inter-assay imprecision were 4.1% and 2.9%, respectively, for dexamethasone concentrations of 1.5, 6.0 and 12.0 nmol/L. Matrix effects were found to be negligible at 106-109% with recovery ranging from 96 to 100%. The limit of quantitation was 0.25 nmol/L, and structural analogue analysis proved the method to be robust against interferences. Applying a serum dexamethasone cut-off of >3.3 nmol/L was associated with a serum cortisol ≤50 nmol/L in 84/95 individuals. Conclusion We have developed a sensitive and robust liquid chromatography tandem mass spectrometry method for the quantitation of serum dexamethasone. The method can be used to identify false-positive results during the overnight dexamethasone suppression test or for pharmacokinetic studies.

Entities:  

Keywords:  Cushing’s syndrome; Dexamethasone; mass spectrometry; overnight dexamethasone suppression test

Mesh:

Substances:

Year:  2018        PMID: 29534610     DOI: 10.1177/0004563218766566

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  3 in total

1.  Core shell stationary phase for a novel separation of some COVID-19 used drugs by UPLC-MS/MS Method: Study of grapefruit consumption impact on their pharmacokinetics in rats.

Authors:  Sally Tarek Mahmoud; Marwa A Moffid; Rawda M Sayed; Eman A Mostafa
Journal:  Microchem J       Date:  2022-07-15       Impact factor: 5.304

2.  Glucocorticoids regulate AKR1D1 activity in human liver in vitro and in vivo.

Authors:  Nikolaos Nikolaou; Anastasia Arvaniti; Nathan Appanna; Anna Sharp; Beverly A Hughes; Dena Digweed; Martin J Whitaker; Richard Ross; Wiebke Arlt; Trevor M Penning; Karen Morris; Sherly George; Brian G Keevil; Leanne Hodson; Laura L Gathercole; Jeremy W Tomlinson
Journal:  J Endocrinol       Date:  2020-05       Impact factor: 4.286

3.  Differential activity and expression of human 5β-reductase (AKR1D1) splice variants.

Authors:  Nathan Appanna; Hylton Gibson; Elena Gangitano; Niall J Dempster; Karen Morris; Sherly George; Anastasia Arvaniti; Laura L Gathercole; Brian Keevil; Trevor M Penning; Karl-Heinz Storbeck; Jeremy W Tomlinson; Nikolaos Nikolaou
Journal:  J Mol Endocrinol       Date:  2021-03       Impact factor: 5.098

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.